Protein sequences provide insight to SARS-CoV-2 infection, study shows
Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
List view / Grid view
Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
A team has shown that STING activation is a new molecular target in the fight against graft-versus-host disease (GVHD).
A study has used artificial intelligence to reveal adeno-associated virus (AAV) capsid variants for use in gene therapies.
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.
Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.
In a zebrafish model, researchers have found that the protein NAPMT can trigger muscle stem cells to proliferate and heal muscle damage.
CRISPR-Cas9 and stem cell technologies have been used to create a cellular model of acute myeloid leukaemia, revealing therapeutic targets.
A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
Studies in mice have shown that the drug ProAgio is effective at treating pancreatic cancer and triple-negative breast cancer.
The drug EIDD-2801 was shown to prevent SARS-CoV-2 replication and infection of cells in a new mouse model containing human lung tissue.
Through a series of experiments, researchers have identified small drug molecules that can inhibit filoviruses such as Ebola and Marburg.
A new therapeutic approach using the protein IL-21 could optimise the immune system, allowing it to combat HIV.
Researchers have developed a personalised medicine platform that could advance genomic medicine research for cancer.
A team has developed enterocyte-like cells from hiPSCs, which can be used to study the absorption of novel oral drugs.
Researchers have discovered that all childhood neuroblastomas come from sympathoblasts, making them a drug target to treat the condition.